Neurosense Therapeutics Ltd. (NRSN)
NASDAQ:NRSN
Top Page
Neurosense Therapeutics Ltd.
(NASDAQ:NRSN)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.89
▲(7.35% Upside)
Action:ReiteratedDate:01/09/26
The score is primarily constrained by weak financial performance (no revenue, widening losses, and increasing cash burn), which elevates funding and dilution risk. Technical signals are mixed with a weak longer-term trend despite neutral momentum, and valuation is limited by negative earnings and no dividend support.
Positive Factors
Phase 3 FDA Clearance
FDA clearance to initiate the pivotal PARAGON Phase 3 trial (300 participants, U.S. and EU) materially advances the regulatory pathway for PrimeC. A successful Phase 3 would de-risk commercialization, enable larger-scale evidence generation, and strengthen the company’s strategic position in ALS over the medium term.
Negative Factors
No Revenue
The company remains pre-revenue with no product sales history, making future cash generation contingent on successful clinical development, regulatory approvals, or partnerships. This structural revenue absence increases execution risk and prolongs reliance on external financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Phase 3 FDA Clearance
FDA clearance to initiate the pivotal PARAGON Phase 3 trial (300 participants, U.S. and EU) materially advances the regulatory pathway for PrimeC. A successful Phase 3 would de-risk commercialization, enable larger-scale evidence generation, and strengthen the company’s strategic position in ALS over the medium term.
Read all positive factors
Neurosense Therapeutics Ltd. (NRSN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$24.65M
Dividend YieldN/A
Average Volume (3M)944.42K
Price to Earnings (P/E)―
Beta (1Y)1.22
Revenue GrowthN/A
EPS Growth31.09%
CountryUS
Employees17
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.23
Shares Outstanding29,699,320
10 Day Avg. Volume256,142
30 Day Avg. Volume944,423
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)8.64
Price to Sales (P/S)0.00
P/FCF Ratio-2.20
Enterprise Value/Market Cap0.80
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.32
Forecast
1Y Price Target
$6.50Price Target Upside683.13% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$714.07K
Neurosense Therapeutics Ltd. Business Overview & Revenue Model
Company Description
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation ...
How the Company Makes Money
Neurosense Therapeutics Ltd. generates revenue primarily through funding and partnerships related to its research and development activities. The company may secure revenue from licensing agreements, where larger pharmaceutical companies pay upfro...
Neurosense Therapeutics Ltd. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
44
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | -89.00K | -3.00K | -3.00K |
| EBITDA | -8.55M | -9.88M | -9.64M | -12.23M | -2.88M | -2.83M |
| Net Income | -8.66M | -10.21M | -10.11M | -12.34M | -4.04M | -2.83M |
Balance Sheet | ||||||
| Total Assets | 1.68M | 4.58M | 3.18M | 7.71M | 11.43M | 779.00K |
| Cash, Cash Equivalents and Short-Term Investments | 666.00K | 3.38M | 2.64M | 7.09M | 11.06M | 699.00K |
| Total Debt | 0.00 | 73.00K | 142.00K | 211.00K | 1.83M | 0.00 |
| Total Liabilities | 2.20M | 1.99M | 4.94M | 2.09M | 2.42M | 120.00K |
| Stockholders Equity | -519.00K | 2.58M | -1.87M | 5.62M | 9.01M | 659.00K |
Cash Flow | ||||||
| Free Cash Flow | -2.00K | -10.14M | -8.38M | -7.66M | -1.56M | -704.00K |
| Operating Cash Flow | -2.00K | -10.13M | -8.35M | -7.59M | -1.54M | -695.00K |
| Investing Cash Flow | -7.00 | 1.00K | 3.47M | -3.54M | -17.00K | -9.00K |
| Financing Cash Flow | 651.00 | 10.91M | 3.98M | 3.69M | 11.90M | 508.00K |
Neurosense Therapeutics Ltd. Technical Analysis
Neutral
0.83
Price Trends
0.87
Negative
0.92
Negative
1.18
Negative
Market Momentum
-0.03
Negative
52.55
Neutral
78.74
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRSN, the sentiment is Neutral. The current price of 0.83 is above the 20-day moving average (MA) of 0.80, below the 50-day MA of 0.87, and below the 200-day MA of 1.18, indicating a neutral trend. The MACD of -0.03 indicates Negative momentum. The RSI at 52.55 is Neutral, neither overbought nor oversold. The STOCH value of 78.74 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for NRSN.
Neurosense Therapeutics Ltd. Risk Analysis
Neurosense Therapeutics Ltd. disclosed 69 risk factors in its most recent earnings report. Neurosense Therapeutics Ltd. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 3 New Risks
1.
If a United States person is treated as owning at least 10% of our ordinary shares, such holder may be subject to adverse U.S. federal income tax consequences. Q4, 2023
2.
If we fail to maintain compliance with Nasdaq's continued listing requirements, our shares may be delisted from the Nasdaq Capital Market. Q4, 2023
3.
Environmental, social and corporate governance, or ESG, issues, including those related to climate change and sustainability, may have an adverse effect on our business, financial condition and results of operations and damage our reputation. Q4, 2023
Neurosense Therapeutics Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $54.55M | -0.82 | -62.53% | ― | ― | 35.80% | |
54 Neutral | $81.11M | -5.29 | -3071.15% | ― | 36.89% | 43.58% | |
53 Neutral | $258.22M | -9.09 | -51.83% | ― | ― | 92.89% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $24.65M | -5.10 | ― | ― | ― | 31.09% | |
44 Neutral | $7.62M | -1.49 | -92.74% | ― | 280.77% | 32.82% | |
43 Neutral | $26.71M | -2.94 | -108.76% | ― | -100.00% | 33.44% |
* Healthcare Sector Average
NRSN
Neurosense Therapeutics Ltd.
0.83
-0.14
-14.43%
TENX
Tenax Therapeutics
15.02
9.27
161.13%
CLGN
Collplant Holdings
0.53
-1.87
-77.95%
KZR
Kezar Life Sciences
7.40
3.05
70.11%
XCUR
Exicure
4.19
-8.61
-67.27%
NRXS
NeurAxis, Inc.
7.25
5.55
326.47%
Neurosense Therapeutics Ltd. Corporate Events
NeuroSense Shareholders Approve Equity Grants to Directors and CEO to Preserve Cash
Jan 6, 2026
On December 30, 2025, NeuroSense Therapeutics held a Special Meeting of Shareholders at which investors approved three equity-related resolutions: grants of restricted shares to the company’s non-management directors for 2024, additional res...
NeuroSense Reports Favorable Safety Profile for PrimeC in Phase 2 Alzheimer’s Trial
Dec 22, 2025
On December 22, 2025, NeuroSense Therapeutics reported that a safety analysis from its proof-of-concept Phase 2, randomized, double-blind, placebo-controlled NST-AD-001 study of PrimeC in Alzheimer’s disease showed a favorable tolerability p...
NeuroSense Completes Data Collection for Alzheimer’s Trial
Dec 8, 2025
NeuroSense Therapeutics Ltd. announced the completion of data collection for its Phase 2 clinical trial of PrimeC in Alzheimer’s disease, known as the RoAD study, on December 8, 2025. The database lock signifies the trial’s readiness f...
NeuroSense Therapeutics Plans Pre-NDS Meeting with Health Canada for ALS Drug
Dec 4, 2025
On December 4, 2025, NeuroSense Therapeutics announced plans for a pre-NDS meeting with Health Canada in April 2026 to discuss the regulatory advancement of PrimeC for ALS. The company is optimistic about the regulatory pathway in Canada and antic...
NeuroSense Gains FDA Approval for Phase 3 ALS Trial
Nov 24, 2025
NeuroSense Therapeutics Ltd. announced on November 24, 2025, that it has received FDA clearance to initiate a pivotal Phase 3 clinical trial for its lead drug candidate, PrimeC, for the treatment of ALS. This trial, named PARAGON, will be conducte...
NeuroSense Therapeutics Schedules Shareholder Meeting to Approve Equity Compensation
Nov 21, 2025
NeuroSense Therapeutics Ltd. has announced a Special Meeting of Shareholders scheduled for December 30, 2025, to discuss and vote on the approval of restricted share grants to non-management directors and the CEO, Alon Ben-Noon. These grants are i...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.